Anika Historical Cash Flow
| ANIK Stock | USD 16.04 0.58 3.49% |
Analysis of Anika Therapeutics cash flow over time is an excellent tool to project Anika Therapeutics future capital expenditures as well as to predict the amount of cash needed to cover cost of sales, R&D expenses or production expansions. Investors should almost always look for trends in cash flow indicators such as Other Non Cash Items of 73.4 M or Capital Expenditures of 4 M as it is a great indicator of Anika Therapeutics ability to facilitate future growth, repay debt on time or pay out dividends.
Financial Statement Analysis is much more than just reviewing and examining Anika Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Anika Therapeutics is a good buy for the upcoming year.
Anika |
About Anika Cash Flow Analysis
The Cash Flow Statement is a financial statement that shows how changes in Anika balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which Anika's non-liquid assets can be easily converted into cash.
Anika Therapeutics Cash Flow Chart
Add Fundamental
Capital Expenditures
Capital Expenditures are funds used by Anika Therapeutics to acquire physical assets such as property, industrial buildings or equipment. This type of outlay is used by management to increase the scope of Anika Therapeutics operations. These expenditures can include everything from repairing an office equipment, building a brand new facility, or writing new software.Stock Based Compensation
Compensation provided to employees in the form of equity or options to purchase company stock. This type of compensation is used to align the interests of employees and shareholders.Change Receivables
The difference in the amount of accounts receivable from one accounting period to the next. A positive number indicates an increase in receivables, while a negative number indicates a decrease.Most accounts from Anika Therapeutics' cash flow statement are interrelated and interconnected. However, analyzing cash flow statement accounts one by one will only give a small insight into Anika Therapeutics current financial condition. On the other hand, looking into the entire matrix of cash flow statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Anika Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. For more information on how to buy Anika Stock please use our How to buy in Anika Stock guide.At this time, Anika Therapeutics' Depreciation is quite stable compared to the past year. Other Non Cash Items is expected to rise to about 73.4 M this year, although the value of Free Cash Flow is projected to rise to (6.9 M).
| 2021 | 2022 | 2023 | 2024 (projected) | Begin Period Cash Flow | 95.8M | 94.4M | 86.3M | 54.1M | End Period Cash Flow | 94.4M | 86.3M | 72.9M | 54.9M |
Anika Therapeutics cash flow statement Correlations
Click cells to compare fundamentals
Anika Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Anika Therapeutics cash flow statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change To Inventory | (5.6M) | (14.2M) | (6.6M) | (6.9M) | (11.4M) | (10.8M) | |
| Change In Cash | 68.4M | (61.6M) | (1.4M) | (8.1M) | (13.5M) | (12.8M) | |
| Free Cash Flow | 34.2M | 11.4M | 3.3M | (3.1M) | (7.2M) | (6.9M) | |
| Change In Working Capital | (6.6M) | (13.5M) | (14.7M) | (11.8M) | (12.1M) | (11.5M) | |
| Other Cashflows From Financing Activities | (293K) | (3.2M) | (6.6M) | (4.6M) | (1.3M) | (1.3M) | |
| Depreciation | 6.0M | 13.5M | 14.3M | 14.5M | 14.2M | 14.9M | |
| Other Non Cash Items | 3.6M | 35.2M | (4.7M) | 7.6M | 69.9M | 73.4M | |
| Capital Expenditures | 2.8M | 1.6M | 5.1M | 7.5M | 5.4M | 4.0M | |
| Total Cash From Operating Activities | 37.0M | 13.1M | 8.4M | 4.4M | (1.8M) | (1.7M) | |
| Net Income | 27.2M | (24.0M) | 4.1M | (14.9M) | (82.7M) | (78.5M) | |
| Total Cash From Financing Activities | (8.1M) | (3.8M) | (6.8M) | (4.9M) | (6.3M) | (6.0M) | |
| End Period Cash Flow | 157.5M | 95.8M | 94.4M | 86.3M | 72.9M | 54.9M | |
| Begin Period Cash Flow | 89.0M | 157.5M | 95.8M | 94.4M | 86.3M | 54.1M | |
| Total Cashflows From Investing Activities | 39.7M | (71.3M) | (3.1M) | (7.5M) | (6.7M) | (7.1M) | |
| Change To Account Receivables | (1.8M) | 5.9M | (6.2M) | (5.6M) | (1.3M) | (1.4M) | |
| Change To Liabilities | 3.5M | (1.4M) | 1.1M | 3.0M | 3.4M | 3.6M | |
| Other Cashflows From Investing Activities | 42.5M | 25.0M | 2.0M | (7.5M) | (8.6M) | (8.2M) | |
| Change To Netincome | 9.3M | 24.5M | (3.5M) | 14.8M | 17.0M | 17.8M | |
| Stock Based Compensation | 6.1M | 5.4M | 11.1M | 14.3M | 15.2M | 14.5M | |
| Change Receivables | (1.8M) | 5.9M | (6.2M) | (5.6M) | (5.1M) | (4.8M) | |
| Cash And Cash Equivalents Changes | 68.4M | (62.0M) | (1.5M) | (7.9M) | (7.1M) | (6.8M) | |
| Cash Flows Other Operating | (1.5M) | 8.9M | 13.0M | 7.4M | 8.5M | 8.9M | |
| Investments | 42.5M | 25.0M | 2.5M | (7.5M) | (6.1M) | (5.8M) | |
| Change To Operating Activities | 1.1M | (3.9M) | 528K | (2.7M) | (2.4M) | (2.3M) |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Trending Equities to better understand how to build diversified portfolios, which includes a position in Anika Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. For more information on how to buy Anika Stock please use our How to buy in Anika Stock guide.You can also try the Funds Screener module to find actively-traded funds from around the world traded on over 30 global exchanges.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Anika Therapeutics. If investors know Anika will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Anika Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.51) | Earnings Share (6.64) | Revenue Per Share 11.139 | Quarterly Revenue Growth (0.07) | Return On Assets (0.04) |
The market value of Anika Therapeutics is measured differently than its book value, which is the value of Anika that is recorded on the company's balance sheet. Investors also form their own opinion of Anika Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Anika Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Anika Therapeutics' market value can be influenced by many factors that don't directly affect Anika Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Anika Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Anika Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Anika Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.